http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. (HealthDay)—Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer and neutropenia who are at low risk of complications, according to a study published online Jan. 28 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2013-01-moxifloxacin-monotherapy-equivalent-antibiotic-combo.html Cancer Wed, 30 Jan 2013 14:40:02 EST news278778144 (HealthDay)—The American Society of Clinical Oncology has issued updated recommendations for both the prevention and management of febrile episodes in neutropenic oncology outpatients; the recommendations have been published online Jan. 14 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2013-01-asco-issues-guideline-febrile-neutropenia.html Cancer Tue, 15 Jan 2013 13:08:16 EST news277477682 (HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to research published in the Oct. 1 issue of Clinical Cancer Research. http://medicalxpress.com/news/2012-11-optimal-dose-dasatinib-ovarian-cancer.html Cancer Mon, 19 Nov 2012 10:00:13 EST news272540632 (HealthDay)—New evidence-based guidelines have been compiled on the management of fever and and neutropenia (FN) in children with cancer and/or who are undergoing hematopoietic stem-cell transplantation; the guidelines were published online Sept. 17 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-09-guidelines-issued-pediatric-fever-neutropenia.html Cancer Wed, 19 Sep 2012 18:20:01 EST news267296979 Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the number of white blood cells falls below a critical threshold, the risk of infection is thought to be high. A new model built by Weizmann Institute mathematicians in collaboration with physicians from the Meir Medical Center in Kfar Saba and from the Hoffmann-La Roche research center in Basel, Switzerland, suggests that for proper risk assessment, it is essential to evaluate not only the quantity of these blood cells, but also their quality, which varies from one person to another. http://medicalxpress.com/news/2012-09-mathematical-safer-chemotherapy.html Medical research Wed, 12 Sep 2012 03:44:43 EST news266640272 (HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release. http://medicalxpress.com/news/2012-08-drug-lack-white-blood-cells.html Medications Thu, 30 Aug 2012 17:40:01 EST news265563649 (HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission, according to the results of a phase II study published online May 21 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-05-brentuximab-vedotin-effective-large-cell-lymphoma.html Cancer Thu, 24 May 2012 18:00:01 EST news257100621 (HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-05-chemo-combination-multiple-myeloma.html Cancer Wed, 02 May 2012 15:30:01 EST news255188297 (HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-03-bevacizumab-hiv-linked-kaposi-sarcoma.html Cancer Tue, 20 Mar 2012 10:19:27 EST news251457546 Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC). http://medicalxpress.com/news/2011-07-amrubicin-response-progression-free-survival-topotecan.html Cancer Thu, 07 Jul 2011 06:49:25 EST news229240151